These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 3865875)

  • 1. Macrovascular disease in diabetes mellitus. Pathogenesis and prevention. International workshop, Garmisch-Grainau, October 1984.
    Horm Metab Res Suppl; 1985; 15():1-122. PubMed ID: 3865875
    [No Abstract]   [Full Text] [Related]  

  • 2. Hyperinsulinemia as a possible risk factor of macrovascular disease in diabetes mellitus. Proceedings of an international workshop. Saint-Paul-de-Vence, Nice, France, January 29-30, 1987.
    Diabete Metab; 1987 Jul; 13(3 Pt 2):277-394. PubMed ID: 3308555
    [No Abstract]   [Full Text] [Related]  

  • 3. Current concepts and controversies in the pathogenesis, prevention, and treatment of the macrovascular complications of diabetes.
    Mazzone T
    J Lab Clin Med; 2000 Jun; 135(6):437-43. PubMed ID: 10850642
    [No Abstract]   [Full Text] [Related]  

  • 4. Pathogenic concepts of diabetic microangiography. International Workshop Garmisch-Grainau, 1980.
    Horm Metab Res Suppl; 1981; 11():1-127. PubMed ID: 6119286
    [No Abstract]   [Full Text] [Related]  

  • 5. [Contemporary view on the pathogenesis of diabetic macroangiopathy].
    Gasińska T
    Wiad Lek; 1998; 51 Suppl 2():40-4. PubMed ID: 9686532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pathogenesis and prevention diabetes mellitus vascular complications].
    Balabolkin MI; Kreminskaia VM
    Ter Arkh; 1999; 71(10):5-12. PubMed ID: 10612165
    [No Abstract]   [Full Text] [Related]  

  • 7. Type 2 diabetes mellitus: prevention of macrovascular complications.
    Meeuwisse-Pasterkamp SH; van der Klauw MM; Wolffenbuttel BH
    Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):323-41. PubMed ID: 18327994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of oral antihyperglycemic agents in modifying macrovascular risk factors in type 2 diabetes.
    Lebovitz HE
    Diabetes Care; 1999 Apr; 22 Suppl 3():C41-4. PubMed ID: 10189561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological treatment of diabetic patients with respect to prevention of macrovascular disease.
    Tkác T
    Acta Diabetol; 2003 Dec; 40 Suppl 2():S338-42. PubMed ID: 14704865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of microvascular and macrovascular complications in diabetes mellitus.
    Maji D
    J Indian Med Assoc; 2004 Aug; 102(8):426, 428, 430 passim. PubMed ID: 15719805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors of macrovascular disease in diabetes mellitus.
    Jarrett RJ
    Horm Metab Res Suppl; 1985; 15():1-3. PubMed ID: 3865876
    [No Abstract]   [Full Text] [Related]  

  • 12. [Diabetes and coronary heart disease frequently appear together. New guidelines regulate therapy and prevention].
    MMW Fortschr Med; 2006 Oct; 148(41):10-1. PubMed ID: 17190248
    [No Abstract]   [Full Text] [Related]  

  • 13. Diet and lifestyle guidelines and desirable levels of risk factors for the prevention of diabetes and its vascular complications in Indians: a scientific statement of The International College of Nutrition. Indian Consensus Group for the Prevention of Diabetes.
    Singh RB; Rastogi SS; Rao PV; Das S; Madhu SV; Das AK; Sahay BK; Fuse SM; Beegom R; Sainani GS; Shah NA
    J Cardiovasc Risk; 1997 Jun; 4(3):201-8. PubMed ID: 9475675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular disease risk markers in diabetes: monitoring & intervention.
    Winters S; Jernigan V
    Nurse Pract; 2000 Jun; 25(6 Pt 1):40, 43-6, 49 passim; quiz 65-7. PubMed ID: 10884996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of macrovascular disease in diabetes mellitus.
    Das T; Gupta P; Dasgupta SB
    J Indian Med Assoc; 1997 Feb; 95(2):48-50, 52. PubMed ID: 9357243
    [No Abstract]   [Full Text] [Related]  

  • 16. Diabetes-associated macrovasculopathy: pathophysiology and pathogenesis.
    Rahman S; Rahman T; Ismail AA; Rashid AR
    Diabetes Obes Metab; 2007 Nov; 9(6):767-80. PubMed ID: 17924861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Microangiopathic complications in type 2 diabetes].
    Strojek K; Grzeszczak W
    Wiad Lek; 1998; 51 Suppl 2():45-51. PubMed ID: 9686533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Diabetes Control and Complications Trial Study: implications for the diabetic foot.
    DeFronzo RA; Reasner C
    J Foot Ankle Surg; 1994; 33(6):551-6. PubMed ID: 7894400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ACE inhibitors and antihypertensive treatment in diabetes: focus on microalbuminuria and macrovascular disease.
    Mogensen CE
    J Renin Angiotensin Aldosterone Syst; 2000 Sep; 1(3):234-9. PubMed ID: 11881030
    [No Abstract]   [Full Text] [Related]  

  • 20. Fibrocalculous pancreatic diabetes and macrovascular disease.
    Unnikrishanan AG; Sahay RK; Bhadada SK; Agrawal NK; Singh SK; Agrawal JK
    J Assoc Physicians India; 2001 Nov; 49():1131, 1133. PubMed ID: 11868882
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.